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Background and PurposeaaThe LRRK2 (PARK8; OMIM607060) substitution was recently 
identified as a causative mutation for Parkinson’s disease (PD). The pathologic heterogeneity 
of LRRK2-positive patients suggests that mutation of the LRRK2 gene is associated with the 
pathogenesis of PD and Parkinson-plus disorders, such as multiple system atrophy (MSA). We 
previously reported that the G2019S LRRK2 mutation-which is the most common LRRK2 mu-
tation-was not found in a sample of 453 Korean PD patients. In the present study, we extended 
the screening for the G2019S mutation to a larger group of PD and MSA patients. 
MethodsaaWe performed a genetic analysis of the G2019S mutation in 877 patients with PD 
and 199 patients with MSA using a standard PCR and restriction digestion method. 
ResultsaaNone of the subjects carried the G2019S mutation. 
ConclusionsaaThe results of the present study support that the G2019S mutation is extremely 
rare in PD and is unlikely to be associated with MSA in the Korean population. 
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Introduction 
 
Several causative mutations of Parkinson’s disease (PD) have 
been identified, the most recent of which is the pathogenic 
LRRK2 (PARK8; OMIM607060) substitution.
1,2 Funayama 
and colleagues reported genetic linkage to chromosome 12 in 
a large Japanese family
3 and subsequently in two Caucasian 
families.
1,2 Mutation of LRRK2 is of great clinical importance 
because the LRRK2 gene has been reported to be present in 
both familial and sporadic forms of PD.
4,5 Several LRRK2 
pathogenic mutations have been reported previously, of which 
the G2019S substitution is the most common.
5-7 Mutation of 
the LRRK2 gene has been reported worldwide, with a wide 
ethnicity variability, and patients with LRRK2 mutations ac-
count for 3-7% of familial PD cases and 0.5-3% of sporadic 
cases of PD.
5-7 LRRK2 mutations are frequent in North Af-
rican Arabs,
8 Jews,
9 and some Spanish populations
10 (6.1-
41% in sporadic PD and 18.7-37% in familial PD), but they 
are very rare in Asian populations.
6,11-14 Clinically, most pa-
tients with LRRK2 mutations have late-onset typical idiopath-
ic PD; however, a pleomorphic pathology-including Lewy 
bodies, tau-positive and/or ubiquitin inclusions-has also been 
reported.
2,15-18 Therefore, investigation of LRRK2 mutations 
has been extended to other neurodegenerative diseases, such 
as progressive supranuclear palsy, multiple system atrophy 
(MSA), and frontotemporal dementia,
19-22 and the G2019S 
mutation was found in a single case of Alzheimer’s disease.
22 
We previously reported that the G2019S mutation was not 
found in a sample of 453 Korean PD patients.
14 Therefore, in 
the present study we extended the screening of the G2019S 
mutation to a larger group of Korean patients with PD and 
MSA. 
 
Methods 
 
All of the patients included in the study were native Koreans 
who were personally examined and followed by the senior 
neurologist at Seoul National University Hospital between  
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1993 and 2006. Blood samples were collected from 2003 with 
written consents from the patients. DNA was extracted and 
stored in a deep freezer until analysis. The genetic study was 
approved by the Institutional Review Board (IRB) of Seoul 
National University Hospital. PD was diagnosed according 
to the criteria of the United Kingdom Parkinson’s Disease 
Society Brain Bank,
23 with the exception of the criterion of 
a positive family history. All MSA subjects were diagnosed 
as having probable MSA according to the Consensus Crite-
ria.
24 
A total of 1,076 parkinsonian subjects were included in this 
study, of which 877 patients had PD (including the 453 sub-
jects previously reported
14) and 199 had MSA. The age of the 
PD patients at onset was 55.7±11.2 years (mean±SD) and 
ranged from 12 to 81 years. Twenty-seven of the 877 PD pa-
tients (3.1%) had at least one first-degree relative (parent or 
sibling) with parkinsonism. There were 265 patients with PD 
who were younger than 50 years at the onset of PD, and 389 
of the PD patients were men (age at onset=55.2±12.2 years) 
and 488 were women (age at onset=56.0±10.4 years). The 
age of the MSA patients at onset was 60.6±8.1 years and ra-
nged from 36 to 83 years. Ninety-four of the MSA patients 
were men (age at onset=62.1±8.0 years) and 105 were wom-
en (age at onset=59.4±8.0 years). 
Genetic analysis was performed as described previous-
ly.
14 Briefly, DNA was extracted from peripheral blood using 
stand-ard methodologies. We used 50 ng of DNA template 
and generated PCR products using the following primer pair 
based on National Center for Biotechnology Information 
(NCBI) accession number NC_000012.10: forward, 5’-AA 
GGGACAAAGTGAGCACAGA-3’; reverse, 5’-TGTTTTC 
CTTTTGACTCTTCTGA-3’. The PCR conditions were an 
initial denaturation at 95℃  for 10 minutes, followed by 35 
cycles of 95℃ for 30 seconds, 60℃ for 30 seconds, and 
72℃ for 1 minute, and a final extension at 72℃ for 7 min-
utes. The PCR products (3 μL) were digested with SfcI (New 
England BioLabs, Beverly, MA, USA) at 37℃. 
Wild-type PCR products produced fragments of 251 and 
127 bp, and the mutant produced fragments of 230, 127, and 
21 bp. Since we did not have a positive control, we used the 
677C>T mutant DNAs of the methylene tetrahydrofolate re-
ductase (MTHFR) gene with similar fragments sizes (175 and 
23 bp) for controlling the quality of restriction digestion and 
electrophoretic separation. Several samples were sequenced 
to confirm the quality of our methods. 
 
Results 
 
None of the 1,076 study subjects (877 PD and 199 MSA) car-
ried the G2019S mutation. 
Discussion 
 
The etiology of PD involves multiple environmental and ge-
netic factors.
4,5,25,26 Until the recent discovery of a causative 
mutation of PD, environmental factors had been emphasized 
in the pathogenesis of PD because most cases of PD are spo-
radic and only 5-10% of patients with PD have one or more 
affected relatives.
27 The identification of familial PD and the 
discovery of genetic abnormalities led to genetic factors be-
coming a primary focus in the field of PD research, and stud-
ies on several causative mutations of PD have furthered our 
understanding of the molecular processes involved in the path-
ogenesis of PD.
4,5,25 Nevertheless, analyses of genetic factors 
in PD have their own limitations, since these mutations are 
usually found in familial cases on rare occasions. Recently dis-
covered LRRK2 mutations have received considerable atten-
tion due to their prevalence in sporadic PD being higher than 
those of other causative mutations.
4,5,25 
Patients with LRRK2 mutations usually show late-onset 
typical PD features,
6 and PD associated with mutation of 
the LRRK2 gene can have a diverse clinical spectrum. Some 
mutation carriers exhibit autonomic and cognitive dysfunc-
tions.
22,28,29 More than 20 putative pathogenic mutations of 
the LRRK2 gene have been identified,
7,30 6 of which (R1441C, 
R1441G, R1441H, Y1699C, G2019S, and I2020T) have been 
reported in more than two unrelated families.
6,7,30 The clini-
cal manifestation does not differ according to the type of sub-
stitution in the LRRK2 gene.
6 The penetrance of LRRK2 mu-
tations appears to differ from that of other causative mutations. 
LRRK2 mutations have an autosomal dominant pattern of in-
heritance with incomplete and age-related penetrance.
1-3,5,31,32 
Therefore, these patients could be reported as late onset with 
sporadic presentation.   
It is well known that the G2019S mutation is the most fre-
quent of several amino acid substitutions in the LRRK2 gene.
5-7 
However, the prevalence of the G2019S LRRK2 mutation ap-
pears to vary with ethnicity, with it being frequent in Western 
populations but very rare (<0.01%) in Asian populations.
5-10 
Several studies designed to screen for the G2019S substitu-
tion in Asian populations produced negative results.
11-13 We 
previously reported that the G2019S mutation was not found 
in a sample of 453 Korean PD patients,
14 and the present study 
further confirms the rarity of the G2019S mutation in PD in 
Korean and Asian populations. Until now, only four cases of 
LRRK2 G2019S substitution have been reported in Asian 
populations,
6,33,34 with other types of substitutions being more 
frequent.
15,20,35 Therefore, further investigations are necessary 
to fully screen for other types of substitution in Korean PD 
patients. 
In this study, we extended the G2019S screening to MSA  
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patients due to the pleomorphic pathology and clinically in-
distinguishable cases of MSA found in studies of patients 
with LRRK2 mutations. LRRK2 mutations usually lead to 
the development of the typical features of late-onset PD; how-
ever, some carriers of the G2019S LRRK2 mutation showed 
severe autonomic dysfunctions that were indistinguishable 
from those of MSA.
22 In addition, autopsy findings have re-
vealed diverse pathologies. LRRK2 mutations have a pleo-
morphic pathology, including the classical changes seen in 
PD such as Lewy bodies, nigral degeneration without Lewy 
bodies, tau-positive and ubiquitin inclusions.
2,15-18 LRRK2 
mutations have recently or been studied in patients with MSA. 
Tan et al.
20 screened for 14 mutations of the LRRK2 gene 
and did not find any mutations in 15 MSA Singaporean sub-
jects. The North American MSA study group
21 and Ross et 
al.
22 did not find the G2019S mutation in 136 clinically dia-
gnosed and 43 pathologically confirmed cases of MSA, re-
spectively. Our finding that the G2019S mutation was not 
present in 199 Korean MSA patients is consistent with pre-
vious reports that the G2019S mutation does not cause MSA. 
The rarity of LRRK2 mutations in our population needs to 
be confirmed by screening all 51 exons of the LRRK2 gene, 
since substitutions other than G2019S in the LRRK2 gene are 
reportedly more frequent in Asian populations. 
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